Basic Information


GTO ID GTC3594
Trial ID NCT06048185
Disease Stargardt Disease
Altered gene MCO
Therapeutic/Target gene Therapeutic gene
TherapyGene transfer
Treatment MCO-010
Recruitment statusRecruiting
TitleLong Term Follow-up for Participants Who Previously Received a Single Intravitreal Injection of MCO-010 Optogenetic Therapy in the STARLIGHT Study
Year2023
CountryUnited States
Company sponsorNanoscope Therapeutics Inc.
Other ID(s)NTXLTFU-007
Vector information
Vectoradeno-associated virus
ConstructAAV2-MCO
Vector typeadeno-associated virus serotype 2 (AAV2) vector
Transgene/Inserted genemulti-characteristic opsin (MCO) gene

Clinical Result

Cohort 1
Administration route intravitreal injection
Age Child, Adult, Older_Adult
References Efficacy and safety of MCO-010 optogenetic therapy for vision restoration in patients with severe vision loss due to retinitis pigmentosa: A phase 2b randomized, sham-controlled, multi-center, multi-dose, double-masked clinical trial (RESTORE)

Relationship Graph

Overview of Knowledge Graph